The global biosimilars market has been segmented on the basis of type of product. The major
types of biosimilars present in the market include monoclonal antibodies, erythropoietin, insulin, G-
CSF, HGH, and interferon amongst others. The report also highlights the various biosimilar drugs
available in the market, and the biosimilars currently in various phases of clinical trials.
Furthermore, the global biosimilars market has also been segmented on the basis of their
applications. According to the report, oncology is expected to account for the largest share in 2016
due to presence of large number of biosimilars for this indication. Based on geography, the report
divides the market into Europe, Asia-Pacific, North America and Rest of the World. In 2016, Europe
is expected to account for the largest share. Moreover, the report also lists down various mergers
and acquisitions taking place in the global biosimilars industry.
The last section of the report discusses about the prominent players in global biosimilars market.
Market share analysis of these players is also provided in the report. A brief business overview and
financial information about each of these players has been provided, along with their product
portfolios and clinical pipelines. The recent development of every player has also been presented in
the report. Overall, the research contains exhaustive information that will help clients in
formulating market strategies and assessing opportunity areas in the global biosimilars market.
Read Sample report of this Category:
http://www.radiantinsights.com/catalog/healthcare
Table of Contents
1. Analyst View
2. Research Methodology
3. Global Biosimilars Market Outlook 2022
4. Market Dynamics
4.1 Drivers
4.1.1 Growing Geriatric Population
4.1.2 Entry of Biosimilars in the US Market
4.1.3 Ability to Curb Healthcare Cost
4.1.4 Rising Incidences of Chronic Diseases
4.1.5 Government Initiatives
4.2 Challenges
4.2.1 Regulatory Issues
Follow Us: